SciELO - Scientific Electronic Library Online

 
vol.37 issue1Indicators monitoring the process of specialized nutritional supportFollow-up of analytical parameters in Internal Medicine patients to detect adverse events author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

SECO-MELANTUCHE, Raquel; DELGADO-SANCHEZ, Olga  and  ALVAREZ-ARROYO, Laura. Incidence of drug-induced thrombocytopenia in hospitalized patients. Farm Hosp. [online]. 2013, vol.37, n.1, pp.27-34. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.1.42.

Objective: To find out the incidence of drug-induced thrombocytopenia and which medications are implicated, and to establish pharmaceutical activity for its prevention and resolution. Methods: A prospective study was conducted between June and December 2009 in hospitalized patients over 18 years of age with thrombocytopenia. The medications considered to be associated with thrombocytopenia were included in a database drawn up from the bibliography. In a suspected case, the doctor was recommended to discontinue, decrease the dosage or keep the drug under observation; and a follow-up of the patient's platelet count was made in order to classify the relationship between the drug and thrombocytopenia. Results: 273 patients were included (61.5% men) with a mean age of60±15 years. Mean stay was 18± 17 days. TCP incidence was 2.26%. The services most involved were Haematology (56), Intensive Care Medicine (48) and Oncology (40). TCP was moderate in 69% of cases, mild in 26 % and severe in 5%. There were 8 cases of drug-induced thrombocytopenia (0.063% incidence), which were resolved in an average of 7.6 days. The medications related were enoxaparin (2), linezolid (2), tacrolimus (2), thymoglobulin (1) and heparin (1). The doctor was recommended to discontinue the drug (2), decrease the dosage (3) or keep it under observation (3), with 100% acceptance. Conclusions: Pharmaceutical vaiicianon musi incorporate an assessment of ihe platelet couni, as II may contribute bolh lo early Identification of thrombocytopenia, and to following up platelet counts in patients receiving therapy with thrombocytopenia related drugs.

Keywords : Thrombocytopenia; Drug-induced thrombocytopenia; Pharmaceutical Validation.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License